Drug Search Results

Omecamtiv mecarbil

Alternative Names: omecamtiv mecarbil, ck-1827452, amg 423
Latest Update: 2024-12-16
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: MYBPC3 Activator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral,Intravenous

FDA Designation: Fast Track - Heart Failure *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Cytokinetics
Company Location: SOUTH SAN FRANCISCO CA 94080
Company CEO: Robert I. Blum
Additonal Commercial Interests: Amgen

Clinical Description

Map of Global Clinical Trials for Omecamtiv mecarbil

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Heart Failure, Chronic|Heart Failure, Systolic

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
COMET-HF	P3	Recruiting	Heart Failure, Chronic\|Heart Failure, Systolic	2027-09-01

Recent News Events

Date	Type	Title
12/03/2024	News Article	Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/03/2024	News Article	Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction
12/02/2024	News Article	Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
12/02/2024	News Article	Cytokinetics to Participate in December Investor Conferences
04/25/2024	PubMed	Intellectual landscapes and emerging trends of non-steroidal mineralocorticoid receptor antagonists: a bibliometric and visual analysis.
04/20/2024	PubMed	Challenging and target-based shifting strategies for heart failure treatment: An update from the last decades.
03/29/2024	PubMed	New Pharmacotherapeutic Classes for the Management of Heart Failure: A Narrative Review.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions